Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2019—Prelude Corp. presented interim results from its Predict study during a poster presentation at the American Society of Breast Surgeons annual meeting, April 30–May 5, in Dallas (Abstract 581643).
July 2019—HemoSonics announced that its Quantra Hemostasis Analyzer platform and QPlus cartridge have been granted de novo marketing authorization by the FDA and are available for sale in the United States.
July 2019—Roche is expanding its partnership with Bio-Techne by offering chromogenic detection kits for automated in situ hybridization tissue analysis.
June 2019—Ortho Clinical Diagnostics’ Vitros XT MicroSlides have been cleared by the FDA. The product features multitest technology that allows laboratories to run two tests simultaneously on one MicroSlide.
June 2019—BD announced the worldwide availability of its FDA-cleared and CE-marked BD Bactec platelet quality control media to identify contaminated platelet units. The product can be used for quality control testing of leukocyte-reduced apheresis platelet units: leukocyte-reduced single and a pool of up to six units of leukocyte-reduced whole blood platelet concentrates.
June 2019—The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma. Approval was based on Keynote‑426, a randomized, multicenter, open-label trial conducted in 861 patients who had not received systemic therapy for advanced renal cell carcinoma. Patients were enrolled regardless of PD-L1 tumor expression status.
June 2019—Positive data demonstrating the clinical value of ConfirmMDx and SelectMDx (MDxHealth, Irvine, Calif.) for prostate cancer were presented in two moderated posters at the American Urological Association annual meeting, May 1–6 in Chicago.
June 2019—PerkinElmer, in collaboration with Helix, launched a genetic screening test called GenePrism: Actionable Insights, which analyzes a subset of 59 medically actionable genes, including BRCA1 and BRCA2, identified by the American College of Medical Genetics and Genomics.
June 2019—Qiagen and NeuMoDx Molecular are expanding the menu for the NeuMoDx 96 and 288 molecular systems. The companies also announced the commercial availability of the NeuMoDx 96 mid-throughput version of the fully integrated PCR-based systems.
June 2019—GenePOC announced that its GenePOC Carba assay received CE marking. The assay is a qualitative, in vitro diagnostic test designed for the detection and differentiation of the blaKPC, blaNDM, blaVIM, blaOXA-48-like, and blaIMP gene sequences associated with carbapenem nonsusceptibility.
